Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19

Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19

We applied a set of in silico and in vitro assays, compliant with the CiPA (Comprehensive In Vitro Proarrhythmia Assay) paradigm, to assess the risk of chloroquine or hydroxychloroquine‐mediated QT prolongation and Torsades de Pointes (TdP), alone and combined with erythromycin and azithromycin, dru...

Full description

Bibliographic Details
Main Authors: Delaunois, A, Abernathy, M, Anderson, WD, Beattie, KA, Chaudhary, KW, Coulot, J, Gryshkova, V, Hebeisen, S, Holbrook, M, Kramer, J, Kuryshev, Y, Leishman, D, Lushbough, I, Passini, E, Redfern, WS, Rodriguez, B, Rossman, EI, Trovato, C, Wu, C, Valentin, J
Format: Journal article
Language:English
Published: Wiley 2021

Similar Items

Similar Items